D-Wave Quantum Inc. filed a Form 8-K with the SEC on September 15, 2026, disclosing under Regulation FD its participation as a platinum sponsor of Quantum World Congress 2026, scheduled for September 23-25 in College Park, Maryland.
Rocket Pharmaceuticals, Inc. filed a Form 8-K with the SEC on September 15, 2026, disclosing that the company reached alignment with the U.S. Food and Drug Administration on key elements of the global pivotal Phase 2 trial of RP-A501 for the treatment of Danon …
Axon Enterprise, Inc. filed a Form 8-K on September 15, 2026, disclosing a second amendment to its credit agreement and the launch of an offering of 0% Convertible Notes due 2031.
Driven Brands Holdings Inc. filed a Form 8-K on September 15, 2026, disclosing an updated capital allocation strategy that includes a $100 million share repurchase authorization approved by its Board of Directors.
American Express Company filed an 8-K on September 15, 2026, under Item 7.01 (Regulation FD Disclosure), furnishing delinquency and write-off statistics for its U.S. Consumer and U.S. Small Business Card balances held for investment for the months ended August 31, July 31, and June …
BlossomHill Therapeutics, Inc. filed a Form 8-K with the SEC on September 15, 2026, disclosing updated clinical data from its ongoing Phase 1/2 SOLARA trial of BH-30643 in non-small cell lung cancer patients, presented at the IASLC 2026 World Conference on Lung Cancer.
Corteva, Inc. filed a current report on September 15, 2026, disclosing that its board of directors approved the spin-off of its seed operating segment into a new independent, publicly traded company called Vylor, Inc., with a distribution record date of September 24, 2026, and …
Lindblad Expeditions Holdings, Inc. filed a Form 8-K on September 15, 2026, disclosing that a subsidiary entered into a Purchase Agreement on September 14, 2026 to acquire a 60% controlling interest in White Desert Ltd, PNR Airways Ltd, and Echo Charlie Ltd for an …
Cushman & Wakefield Ltd. filed a Form 8-K on September 15, 2026, disclosing that its Senior Vice President, Chief Accounting Officer and Global Corporate Controller, Laurida Sayed, notified the company of her resignation effective September 25, 2026.
LB Pharmaceuticals Inc filed a Form 8-K with the SEC on September 15, 2026, disclosing the appointment of Susan G. Kozauer, M.D. as Chief Medical Officer, effective September 14, 2026.